Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Gains from Investment Securities (2021 - 2025)

Bioadaptives' Gains from Investment Securities history spans 3 years, with the latest figure at $500000.0 for Q2 2025.

  • For Q2 2025, Gains from Investment Securities changed N/A year-over-year to $500000.0; the TTM value through Jun 2025 reached $500000.0, changed N/A, while the annual FY2021 figure was $90219.0, N/A changed from the prior year.
  • Gains from Investment Securities for Q2 2025 was $500000.0 at Bioadaptives, up from -$272965.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $500000.0 in Q2 2025 and bottomed at -$387723.0 in Q3 2021.
  • The 3-year median for Gains from Investment Securities is $110210.0 (2022), against an average of $84317.0.
  • The largest YoY upside for Gains from Investment Securities was 128.42% in 2022 against a maximum downside of 402.56% in 2022.
  • A 3-year view of Gains from Investment Securities shows it stood at $90219.0 in 2021, then tumbled by 402.56% to -$272965.0 in 2022, then surged by 283.17% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Gains from Investment Securities are $500000.0 (Q2 2025), -$272965.0 (Q4 2022), and $110210.0 (Q3 2022).